Navigation Links
Schizophrenic in Medical News

Improving the prognosis for schizophrenic disorders

Throughout the world, scientists are attempting to recognize and treat schizophrenic disorders at an earlier stage. It is hoped that this will improve the prognosis, which has often been unfavorable. In the latest edition of Deutsches rzteblatt International ( Dtsch Arztebl Int 2008; 105[30]: 5...

Cognitive rehabilitation holds promise for schizophrenic brain function improvements

Study had shown that it is possible to improve the brain functions of schizophrenic// patients through cognitive rehabilitation programs. Researchers from Washington University in St. Louis have suggested that memorization strategies used by normal people to remember things may be useful for s...

Music to help schizophrenic patients

Scientists have found that in addition to schizophrenic patients being given medical care, music, as a therapy, can bring about changes in their general sense of well being, mental state and social activities.// Since 1950s music had been used as a therapy for people with serious mental disord...

Alexza to Announce 2009 Second Quarter Financial Results and Update Its Clinical Pipeline Status on Wednesday, August 5, 2009

...comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Columbia leads national effort to develop early intervention for schizophrenia

...ders by dramatically slowing progression; reducing disability, mortality, and the expense of care; and increasing recovery. The Recovery After Initial schizophrenic Episode (RAISE) study, funded at $9.9 million for two years, has the potential to be extended to six years and a total of $21.3 million if certain mil...

Study finds cancer is the second most frequent cause of death in individuals with schizophrenia

...tify characteristics that might help predict which schizophrenic patients are likely to develop cancer. The rese...he general population (56.3 vs. 33.0%). In female schizophrenic patients, the risk of death due to breast cancer w...ing less attention to symptoms; the difficulty for schizophrenic patients to benefit from optimum treatment; and le...

Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza's Corporate Presentation to be Webcast at the Piper Jaffray Fourth Annual Europe Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Favorable Vote From FDA Advisory Committee on SEROQUEL Pediatric Supplemental New Drug Applications

...including SEROQUEL. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatmen...

Alexza's Corporate Presentation to be Webcast at the Eighth Annual JMP Securities Research Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

More>>

Schizophrenic in Medical Technology

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

Conference Call Scheduled for Today - Tuesday, September 2, 2008 at 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from its first Phase 3 clinical trial of ...

Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program

...of patients experience continued symptoms despite treatment. The problem with current therapies is that none of them improve the cognitive deficit in schizophrenic patients, and almost all of these drugs have significant side effects, such as weight gain, induction of tremors and psychological depression. ...

Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches

...ndidates in clinical development. Alexza's lead program is AZ-004 (Staccato loxapine) that is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is pro...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

... the positive data from our first Phase 3 trial in schizophrenic patients -- reinforce our belief that AZ-004 is a ...olunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and pharmacokinetic study in non-agitated schizophrenic patients, a 344 patient Phase 3 study in schizophr...

AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia

...mpairments play a primary role in the inability of schizophrenic patients to function normally. It has been estimated that there are 7.9 million schizophrenic patients in the world's seven major pharmaceutical markets and that the majority of all schizophrenic patients are cognitively impaired. About...

Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates

... developed for the treatment of acute agitation in schizophrenic or bipolar disorder patients," said Thomas B. King...ollment in its first Phase 3 clinical trial of 344 schizophrenic patients with acute agitation at 24 U.S. clinical ... loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testin...

Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

...olunteers, a 129 patient Phase 2 study in agitated schizophrenic patients, a 32 patient multiple-dose tolerability and PK study in non-agitated schizophrenic patients, and a 344 patient Phase 3 study in agitated schizophrenic patients. Alexza projects that the initial results...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorper...

Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... Phase 2 study, and a 32 patient multiple-dose tolerability and PK study in schizophrenic patients. The Company believes that the unique delivery of loxapine via t...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...
Schizophrenic in Biological News

Advances in the field of schizophrenia research: New genetic factors identified

...ding to estimates, approximately one in every hundred persons experiences a schizophrenic episode at least once in their lives. In Germany alone there are approximat...proximately 80 percent according to estimations. Thus, close relatives of a schizophrenic patient are more susceptible to fall ill themselves. The hereditary pattern...

Scientists dig deeper into the genetics of schizophrenia by evaluating microRNAs

...ticular gene, such as BRAC1, can be tested and then treated with protocols designed specifically for them, we want to be able to know enough about the schizophrenic brain to target treatments to individual patients. The next step for the researchers is to find the many genes whose expression is controlled by t...

New treatment mechanisms for schizophrenia

...chizophrenia. These findings suggest that 7 nAChR agonists including SSR180711 could be potential therapeutic drugs for cognitive deficits in schizophrenic patients. In the third investigation, Semenova and colleagues show that a recently discovered brain receptor for serotonin (5-HT7) might be of impo...

The influence of the menstrual cycle on the female brain

...can result in disorders such as addictions and is also implicated in various psychiatric and neurological pathologies, such as Parkinson's disease and schizophrenic disorders. Many studies on animals prove that the dopaminergic3 system is sensitive to gonadal steroid hormones (estrogen, progesterone). For example,...

Engineered mouse mimics cognitive aspects of schizophrenia

...cs. The achievement is important, because creating an animal model of any schizophrenic characteristics has not been done before. And schizophrenia's genetic and p...neurons. Also, amphetamines, which release dopamine, are known to aggravate schizophrenic symptoms. The researchers also based their experiments on evidence that ...
Schizophrenic in Biological Technology

Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference

...t comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference

...ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, and is projecting ...

Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation

...ent comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive initial results from both of its AZ-004 Phase 3 clinical trials, and is pro...

Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB

...ro are central nervous system ("CNS") products. Azur Pharma's CNS business currently markets FazaClo(R) in the U.S. for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenia drug treatments. FazaClo is supplied as an innovative orally disintegrating tablet t...

FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania

...ncluding quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment...

Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation

... has five product candidates in active clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed enrollment of its first Phase 3 clinical trial. A second Phase 3 clinical trial ...

Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and completed the enrollment of its first Phase 3 clinical trial in June 2008. AZ-001 (Staccato pr...

Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering

... Alexza has six product candidates in clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed the enrollment of its first Phase 3 clinical trial. AZ-001 (Staccato prochlorper...

Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates

...its first Phase 3 clinical trial, designed to enroll approximately 300 schizophrenic patients with acute agitation at 25 U.S. clinical centers. The trial ...program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing. AZ-001 (Staccato proch...
Other Tags
(Date:8/29/2014)... have been hospitalized for a burn as a child experience ... to new research at the University of Adelaide . ... been conducted by the University,s Centre for Traumatic Stress Studies. ... some form of mental illness and 30% suffered depression at ... in the journal Burns , also found ...
(Date:8/29/2014)... disease outbreaks across the Arabian Peninsula and spread to ... the lives of several hundred people since its discovery ... puzzled over how easily the pathogen spreads from human ... virologists from the University of Bonn have now come ... of human transmission is low. Still, a third of ...
(Date:8/29/2014)... As a chiropractic physician and medical doctor an ... direct connection between the condition of the feet and ... shoe inserts and orthotics weren’t satisfying my patients, I ... said. , Customizable to a user’s needs, the patent-pending ... in order to help prevent pain in the foot, ...
(Date:8/29/2014)... HealthDay Reporter , THURSDAY, Aug. 28, ... days of the Ebola outbreak in West Africa has given ... Researchers report in the Aug. 28 online issue of ... The Ebola strains responsible for the current outbreak ... first recorded outbreak of Ebola in central Africa in 1976. ...
(Date:8/29/2014)... (HealthDay News) -- The way that parents respond to ... a new study suggests. Over six months, researchers ... during free play. The sessions were 30 minutes long ... months old at the start of the study. ... infants began to form complex sounds. The babies whose ...
Breaking Medicine News(10 mins):Health News:Intervention needed for survivors of childhood burns 2Health News:MERS: Low transmissibility, dangerous illness 2Health News:MERS: Low transmissibility, dangerous illness 3Health News:Gene Research Yields Insights Into Ebola Virus 2Health News:Gene Research Yields Insights Into Ebola Virus 3Health News:Encouraging Your Baby's Babbling May Speed Language Development 2
(Date:8/28/2014)... to Research Careers) Program has announced the travel award ... October 18 22, 2014 in San Diego, California. ... of students, post doctorates and scientists from underrepresented groups ... to encourage the participation of young scientists at the ... conferred 16 awards totaling $29,600., The FASEB MARC Program ...
(Date:8/28/2014)... developmental on-off switch for Streptomyces , a group ... the world,s naturally derived antibiotic medicines. , Their ... possible to manipulate this switch to make nature,s antibiotic ... 28 in Cell , found that a unique ... larger protein called BldD ultimately controls whether a bacterium ...
(Date:8/28/2014)... and imaging how quickly blood flows in the brain ... abuse affects the brain, which may aid in improving ... treatment options for recovering drug addicts. The new method, ... University in New York, USA and the U.S. National ... Society,s (OSA) open-access journal Biomedical Optics Express ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
Other Contents